BlackRock, Inc. Amends Schedule 13G/A for Protagonist Therapeutics, Inc.

BlackRock, Inc. has filed an amendment to its Schedule 13G/A for Protagonist Therapeutics, Inc., reporting ownership of 8,575,669 shares, representing 13.8% of the company's common stock. The filing indicates that BlackRock has sole voting power over 8,481,570 shares and sole dispositive power over all 8,575,669 shares. The amendment also notes that the interest of iShares Core S&P Small-Cap ETF in Protagonist Therapeutics' common stock exceeds five percent of the total outstanding shares. The filing was signed by Spencer Fleming, Managing Director of BlackRock, Inc., and was effective as of October 17, 2025. This amendment reflects changes in BlackRock's holdings and provides updated information on its beneficial ownership in Protagonist Therapeutics.